EGFR and cancer: Through bioinformatic analyses in both breast and ovarian cancer cell line panels, they uncovered an intricate network connecting TET1 to hypomethylation and activation of cancer-specific oncogenic pathways, including phosphatidylinositol 3-kinase (PI3K), epidermal growth factor receptor (EGFR), and platelet derived growth factor (PDGF).